The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PRD is also involved in interactions with focal adhesion kinase (FAK),281 peptidase D,282 ASPP family members,283 and the corepressor protein mSin3a.284”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [283]
In the citing paper
“Unlike ASPP2, iASPP preferentially binds p53-PRD283 and interacts with the DBD through the L1 loop, helix H2 and N-terminal loop308 (Fig. 7d).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [283]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
Dumont, P., Leu, J. I.-J., Della Pietra, A. C., George, D. L., & Murphy, M. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,273
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664
Self-citationStructure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 571
Identification of a novel p53 functional domain that is necessary for efficient growth suppression
Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 471
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
Self-citationiASPP oncoprotein is a key inhibitor of p53 conserved from worm to human
Bergamaschi, D., Samuels, Y., O'Neil, N. J., Trigiante, G., Crook, T., Hsieh, J.-K., O'Connor, D. J., Zhong, S., Campargue, I., Tomlinson, M. L., et al. (2003) · Nature Genetics · doi:10.1038/ng1070 · Cited by 371
Self-citationVenot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
To die or not to die: how does p53 decide?
Slee, E. A., O'Connor, D. J., & Lu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 278
Self-citationASPP1 and ASPP2: Common Activators of p53 Family Members
Bergamaschi, D., Samuels, Y., Jin, B., Duraisingham, S., Crook, T., & Lu, X. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1341-1350.2004 · Cited by 228
Self-citationTP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
Matakidou, A., Eisen, T., & Houlston, R. S. (2003) · Mutagenesis · doi:10.1093/mutage/geg008 · Cited by 151
Baptiste, N., Friedlander, P. A., Chen, X., & Prives, C. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205015 · Cited by 149
Trigiante, G., & Lü, X. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1818 · Cited by 135
Zhu, J., Jiang, J., Zhou, W., Zhu, K., & Chen, X. (1999) · Oncogene · doi:10.1038/sj.onc.1202533 · Cited by 117
Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer
Granja, F., Morari, J., Morari, E. C., Correa, L. A. C., da Assumpção, L. V. M., & Ward, L. S. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.016 · Cited by 107
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growthPreprint
Vives, V., Su, J., Zhong, S., Ratnayaka, I., Slee, E. A., Goldin, R. D., & Lü, X. (2006) · Genes & Development · doi:10.1101/gad.374006 · Cited by 105
The expression of iASPP in acute leukemias
Zhang, X., Wang, M., Zhou, C., Chen, S., & Wang, J. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.07.001 · Cited by 82
The Transcriptional Repressor hDaxx Potentiates p53-dependent Apoptosis
Gostissa, M., Morelli, M., Mantovani, F., Guida, E., Piazza, S., Collavin, L., Brancolini, C., Schneider, C., & Sal, G. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310801200 · Cited by 79
Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development
Siddique, M. M., Chowbay, B., Fiszer‐Maliszewska, Ł., Aggarwal, A., Tan, A., Tan, P. B. O., Soo, K. C., & Sabapathy, K. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0153 · Cited by 77
Agirre, X., Román‐Gómez, J., Jiménez‐Velasco, A., Gárate, L., Montiel‐Duarte, C., Navarro, G., Vázquez, I., Zalacaín, M., Calasanz, M. J., Heiniger, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209236 · Cited by 67
Noma, C., Miyoshi, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.031 · Cited by 66
The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization
Slee, E. A., Gillotin, S., Bergamaschi, D., Royer, C., Llanos, S., Ali, S., Jin, B., Trigiante, G., & Lü, X. (2004) · Oncogene · doi:10.1038/sj.onc.1208088 · Cited by 56
Self-citationLossos, I. S., Natkunam, Y., Levy, R., & Lopez, C. D. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000040017 · Cited by 50
Abnormal mRNA expression of ASPP members in leukemia cell lines
Liu, Z.-J., Zhang, Y., Zhang, X., & Yang, X. (2004) · Leukemia · doi:10.1038/sj.leu.2403300 · Cited by 43
D’Erchia, A. M., Pesole, G., Tullo, A., Saccone, C., & Sbisà, E. (1999) · Genomics · doi:10.1006/geno.1999.5794 · Cited by 21
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Metadata
- Authors
- Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., Crook, T., & Lu, X.
- Venue
- Nature Genetics
- Published
- 2006-09-10
- Volume
- 38
- Issue
- 10
- Pages
- 1133-1141
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2152733195
- Cited by
- 259
- References
- 24
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.